Drug repurposing against COVID-19: focus on anticancer agents
Open Access
- 12 May 2020
- journal article
- review article
- Published by Springer Science and Business Media LLC in Journal of Experimental & Clinical Cancer Research
- Vol. 39 (1), 1-9
- https://doi.org/10.1186/s13046-020-01590-2
Abstract
The very limited time allowed to face the COVID-19 pandemic poses a pressing challenge to find proper therapeutic approaches. However, synthesis and full investigation from preclinical studies to phase III trials of new medications is a time-consuming procedure, and not viable in a global emergency, such as the one we are facing. Drug repurposing/repositioning, a strategy effectively employed in cancer treatment, can represent a valid alternative. Most drugs considered for repurposing/repositioning in the therapy of the COVID-19 outbreak are commercially available and their dosage and toxicity in humans is well known, due to years (or even decades) of clinical use. This can allow their fast-track evaluation in phase II–III clinical trials, or even within straightforward compassionate use. Several drugs being re-considered for COVID-19 therapy are or have been used in cancer therapy. Indeed, virus-infected cells are pushed to enhance the synthesis of nucleic acids, protein and lipid synthesis and boost their energy metabolism, in order to comply to the “viral program”. Indeed, the same features are seen in cancer cells, making it likely that drugs interfering with specific cancer cell pathways may be effective as well in defeating viral replication. To our knowledge, cancer drugs potentially suitable for facing SARS-CoV-2 infection have not been carefully reviewed. We present here a comprehensive analysis of available information on potential candidate cancer drugs that can be repurposed for the treatment of COIVD-19.Keywords
This publication has 110 references indexed in Scilit:
- Enhancement of T cell-mediated immune responses to whole inactivated influenza virus by chloroquine treatment in vivoVaccine, 2013
- Rapamycin and mTOR: a serendipitous discovery and implications for breast cancerClinical and Translational Medicine, 2012
- Different host cell proteases activate the SARS-coronavirus spike-protein for cell–cell and virus–cell fusionVirology, 2011
- TORC-Specific Phosphorylation of Mammalian Target of Rapamycin (mTOR): Phospho-Ser2481 Is a Marker for Intact mTOR Signaling Complex 2Cancer Research, 2009
- Anakinra for rheumatoid arthritisEmergencias, 2009
- Tocilizumab: The first interleukin-6-receptor inhibitorAmerican Journal of Health-System Pharmacy, 2008
- Inhibition of human coronavirus 229E infection in human epithelial lung cells (L132) by chloroquine: Involvement of p38 MAPK and ERKAntiviral Research, 2008
- Institutional experience with chloroquine as an adjuvant to the therapy for glioblastoma multiformeSurgical Neurology, 2007
- Non–Small-Cell Lung Cancer Vaccine Therapy: A Concise ReviewJournal of Clinical Oncology, 2005
- Drug repositioning: identifying and developing new uses for existing drugsNature Reviews Drug Discovery, 2004